Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

En studie som jämför Siplizumab med kaninantikropp mot tymocyter för att hjälpa kroppen att acceptera en njurtransplantation (MODERNIZE1)

6 november 2026 uppdaterad av: ITB-Med LLC

Fas 2b, randomiserad, multcenter, dubbelblind, dosfinjusteringsstudie med aktiv kontroll av Siplizumab (TCD601) jämfört med kanin-antitymocytglobulin hos njurtransplantationspatienter som behöver induktionsbehandling och får standardimmunsuppression med tacrolimus, mykofenolsyra och kortikosteroider

The goal of this clinical trial is to learn if siplizumab can prevent rejection of a kidney transplant in adult participants with end stage kidney disease. The main questions it aims to answer are:

How many adverse events do participants receiving two different doses of siplizumab have compared to rabbit anti-thymocyte globulin (rATG)?

How many participants successfully keep their kidney transplant after receiving siplizumab or rATG? This will be calculated as those participants that did not: die; have their kidney fail to work properly (graft loss); their body rejects their transplant (tissue sample (biopsy)-proven acute rejection: BPAR); or who were lost to follow-up.

How does the body respond to siplizumab after dosing at each of the 2 dose levels?

How does siplizumab work in the body compared to rATG?

Selected participants will be divided into 3 groups. In 2 of the groups, participants will be given siplizumab at one of the two study medicine doses. Participants in the third group will be given rATG. All participants will take the usual anti-rejection medicines given before, during, and after a kidney transplant. All participants will also be given medicines before the study drug to lower the risk of reactions, and medicines used to prevent or treat infections after the transplant.

Participants will be asked to provide their medical history at the first visit at the study site where you will have your kidney transplant. At the first visit and other visits participants will be asked to provide their medication history, have a physical exam, check vital signs, have blood drawn for tests, and have non-invasive tests that record the electrical activity of your heart (ECG) and blood draws.

Participants will be monitored for 12 months after transplant surgery.

Studieöversikt

Detaljerad beskrivning

Approximately 120 renal transplant candidates requiring induction therapy will be enrolled 1:1:1 to receive 1 of 2 dose levels of siplizumab or to the comparator rATG.

Randomization will be stratified by donor status (living vs donation after brain death vs donation after cardiac death) to ensure similar proportions of donor types in each study arm. All participants will also receive:

  • A triple regimen (TAC, MPA, and CS) of background immunosuppressive therapy for the duration of the study.
  • Premedication prior to study treatment infusions.
  • Infection prophylaxis

This clinical trial will evaluate the safety of an anti-cluster of differentiation 2 (CD2) monoclonal antibody, siplizumab, compared to rATG as induction therapy in renal transplant recipients.

Following hospital discharge, participants will undergo assessments and procedures as indicated in the protocol through Month 12 or EOS, unless more frequent visits are required per local SoC or for laboratory specimen collection.

Safety assessments will include physical examinations, ECGs, vital signs, viral surveillance and monitoring, standard clinical laboratory evaluations completed centrally (hematology, clinical chemistry, urinalysis), and AE/SAE monitoring.

Final analysis will be performed when all participants have completed 12-month follow-up visits post-transplant or have otherwise ended the trial. This analysis will be performed to evaluate the safety of siplizumab at 2 dose levels compared to rATG.

Studietyp

Interventionell

Inskrivning (Beräknad)

120

Fas

  • Fas 2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Minas Gerais
      • Belo Horizonte, Minas Gerais, Brasilien, 30150-320
        • Rekrytering
        • Santa Casa Demisericordia de Belo Horizonte
        • Kontakt:
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brasilien, 90035-903
        • Rekrytering
        • Hospital de Clinicas de Porto Alegre
        • Kontakt:
      • Porto Alegre, Rio Grande do Sul, Brasilien, 90020-090
        • Rekrytering
        • Santa Casa de Misericordia de Porto Alegre - Hospital Dom Vincente Scherer
        • Kontakt:
    • São Paulo
      • São José do Rio Preto, São Paulo, Brasilien, 15090-000
        • Rekrytering
        • Fundação Faculdade Regional de Medicina de São José do Rio Preto - Centro Integrado de Pesquisa
        • Kontakt:
      • São Paulo, São Paulo, Brasilien, 04038-002
        • Rekrytering
        • Fundação Oswaldo Ramos - Hospital do Rim (HRIM)
        • Kontakt:
    • California
      • Los Angeles, California, Förenta staterna, 90033
        • Rekrytering
        • Keck Hospital of the University of Southern California
        • Kontakt:
      • Los Angeles, California, Förenta staterna, 90095
        • Rekrytering
        • University of California - Los Angeles, Connie Frank Kidney Transplant Center
        • Kontakt:
      • Sacramento, California, Förenta staterna, 95817
        • Rekrytering
        • UC Davis Medical Center
        • Kontakt:
    • Florida
      • Tampa, Florida, Förenta staterna, 33606
        • Rekrytering
        • Tampa General Hospital
        • Kontakt:
    • Georgia
      • Atlanta, Georgia, Förenta staterna, 30322
        • Rekrytering
        • Emory University Hospital
        • Kontakt:
    • Kansas
      • Kansas City, Kansas, Förenta staterna, 66160
        • Rekrytering
        • University of Kansas Hospital
        • Kontakt:
    • Kentucky
      • Lexington, Kentucky, Förenta staterna, 40536
        • Rekrytering
        • University of Kentucky Healthcare
        • Kontakt:
    • Louisiana
      • Metairie, Louisiana, Förenta staterna, 70006
        • Rekrytering
        • Tulane Medical Center
        • Kontakt:
    • Massachusetts
      • Worcester, Massachusetts, Förenta staterna, 01655
    • Michigan
      • Ann Arbor, Michigan, Förenta staterna, 48109
        • Rekrytering
        • University of Michigan - Michigan Medicine
        • Kontakt:
          • Nerissa Reister, Clinical Research Coordinator
          • Telefonnummer: 734-763-5718
          • E-post: naflow@med.umich.edu
      • Detroit, Michigan, Förenta staterna, 48202
        • Rekrytering
        • Henry Ford Health
        • Kontakt:
    • New Jersey
      • Livingston, New Jersey, Förenta staterna, 07039
        • Rekrytering
        • Cooperman Barnabus Medical Center
        • Kontakt:
    • New York
      • New York, New York, Förenta staterna, 10032
        • Rekrytering
        • New York Presbyterian - Columbia University Irving Medical School
        • Huvudutredare:
          • Lloyd Ratner, MD
        • Kontakt:
        • Kontakt:
      • New York, New York, Förenta staterna, 10065
        • Rekrytering
        • New York Presbyterian - Weill Cornell Medical Center
        • Kontakt:
        • Kontakt:
    • North Carolina
      • Durham, North Carolina, Förenta staterna, 27710
        • Rekrytering
        • Duke University Medical Center
        • Kontakt:
    • Texas
      • Dallas, Texas, Förenta staterna, 75390
    • Virginia
      • Falls Church, Virginia, Förenta staterna, 22042
        • Rekrytering
        • Inova Fairfax Hospital
        • Kontakt:
      • Richmond, Virginia, Förenta staterna, 23298
        • Rekrytering
        • Virginia Commonwealth University Health
        • Kontakt:
    • Washington
      • Seattle, Washington, Förenta staterna, 98195
        • Rekrytering
        • University of Washington Medical Center
        • Kontakt:
          • Belinda Pan, Research Coordinator
          • Telefonnummer: 206-598-1562
          • E-post: bcpan@uw.edu
      • Barcelona, Spanien, 08035
        • Rekrytering
        • Hospital Universitari Vall D'Hebron
        • Kontakt:
      • Córdoba, Spanien, 14004
      • Málaga, Spanien, 29010
        • Rekrytering
        • Hospital Universitario Regional de Malaga
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 70 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Recipients of a renal allograft from a non-HLA identical living or deceased donor.
  • Recipients of a kidney with a cold ischemia time < 30 hours; hypothermic machine perfusion within the same timeframe is acceptable.
  • Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, must agree to use highly effective methods of contraception.

Exclusion Criteria:

  • Transplant recipients seronegative for EBV.
  • Transplant recipients receiving a kidney from a non-heart beating donor (ie, DCD) whose organ is retrieved from an uncontrolled DCD or whose donor age > 55 years of age.
  • Multi-organ transplant recipients (eg, kidney-pancreas, organ other than kidney), dual-kidney transplant recipients, recipients with more than one prior kidney transplant, or hematopoietic stem cell transplantation recipients.
  • Presence of current or historical DSA via single-antigen bead assay or local SoC. The MFI cut-off value used to determine the presence of DSA will be defined as per the institutional SoC. Results within 3 months prior to transplant are acceptable.
  • Crossmatch positive (isolated positive B cell crossmatches are not an exclusion criterion).
  • ABO-incompatible recipient.
  • Administration of complement inhibitor therapy within 6 months prior to the transplant, or likely to require treatment with complement inhibitor therapy during the study.
  • Participants receiving immunosuppressive therapies prior to transplant for pre-existing conditions must be candidates for the protocol-defined regimen.
  • History of malignancy of any organ system, except for localized excised non-melanomatous skin lesions or carcinoma in situ of the cervix.
  • Seropositive for human immunodeficiency virus or hepatitis B surface antigen. Participants who are seropositive for hepatitis C virus (HCV) are excluded without proof of sustained viral response after anti-HCV treatment.
  • Recipient of a kidney from a donor who tests positive for human immunodeficiency virus or hepatitis B surface antigen/hepatitis B core protein.
  • History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes (eg, siplizumab, rATG, TAC, MPA derivatives, CS).
  • Evidence of active tuberculosis (TB) infection (participants with a history of latent TB may become eligible after treatment with anti-TB therapy according to national guidelines).
  • Participants with severe systemic infection(s), at the time of screening or within 2 weeks prior to randomization

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Förebyggande
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Fyrdubbla

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Låg dos siplizumab

A non-agonistic, humanized, anti-CD2 monoclonal antibody of the IgG1κ class

Andra namn:
  • TCD601
Experimentell: Hög dos siplizumab

A non-agonistic, humanized, anti-CD2 monoclonal antibody of the IgG1κ class

Andra namn:
  • TCD601
Aktiv komparator: Kanin anti-thymocytglobulin

An anti-human thymocyte immunoglobulin preparation made of purified polyclonal antibodies derived from rabbits

Andra namn:
  • Thymoglobulin

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Assessment of the safety of 2 dose levels of siplizumab versus rATG.
Tidsram: 12 months

Number and percentage of participants at 12 months post-transplant experiencing adverse events (AEs), serious adverse events (SAEs), and adverse events of special interest (AESIs).

12 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Tidsram: 12 months
  • Composite incidence of BPAR, death, graft loss, and loss-to-follow-up.
  • Incidence of participants who experienced BPAR as defined by central pathology (blinded independent central review using Banff Allograft Pathology Scoring).
  • Incidence of treated BPAR and steroid-resistant BPAR.
12 months
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Tidsram: 12 months

• Grade of BPAR.

12 months
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Tidsram: 12 months

• Severity of BPAR.

12 months
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Tidsram: 12 months
  • Time to first BPAR for each participant.
  • Time to graft loss for each participant.
  • Time to death for each participant.
12 months
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Tidsram: 12 months
  • Participant survival at 12 months.
  • Graft survival at 12 months.
12 months
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Tidsram: 12 months

• Number of participants requiring for-cause renal allograft biopsy assessments over 12 months post-transplant.

12 months
Assessment of the pharmacokinetics (PK) of 2 dose levels of siplizumab.
Tidsram: 12 weeks

Siplizumab Cmax (maximum blood concentration) over 12 weeks post-transplant.

12 weeks
Assessment of the pharmacokinetics (PK) of 2 dose levels of siplizumab.
Tidsram: 12 weeks

Siplizumab AUC (area under the concentration-time curve) over 12 weeks post-transplant.

12 weeks
Assessment of the pharmacodynamics (PD) of 2 dose levels of siplizumab versus rATG.
Tidsram: 12 months

Depletion and recovery of lymphocyte count by subset (total lymphocytes; CD3+, CD4+, and CD8+ T cells; CD19+ B cells; CD56+ NK cells) over 12 months post-transplant.

12 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

29 juni 2026

Primärt slutförande (Beräknad)

28 mars 2028

Avslutad studie (Beräknad)

28 mars 2028

Studieregistreringsdatum

Först inskickad

11 mars 2026

Först inskickad som uppfyllde QC-kriterierna

27 mars 2026

Första postat (Faktisk)

2 april 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

12 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

6 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera